This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Leading trade organizations representing the makers of cell and gene therapies are calling for a 10-year international moratorium on the use of CRISPR and other DNA-editing tools to create genetically modified children, according to a draft of the declaration provided to STAT. The move — coming more than seven years after Chinese researcher He Jiankui announced the birth of the world’s first CRISPR babies — is intended to send a clear signal to the global scientific co
Amy Parison, who stepped into the lead financial role at the company in March, is managing Editas Medicine’s transition to a new gene editing platform while recovering from a major overhaul.
Philanthropist Bill Gates announced Thursday that he will wind down his massive charity in 20 years, doubling spending over that time to accelerate the work it hopes to achieve. Gates made the announcement on the 25th anniversary of the launch of the Gates Foundation, the third-largest player in international philanthropy. He said the foundation would spend $200 billion between now and 2045, when its operations will wind down.
Accretion Pharmaceuticals, an Ahmedabad-headquartered pharmaceuticals manufacturer, announced that its initial public offering (IPO) will open for subscription on Wednesday, May 14, 2025. The anchor portion will be opened on Tuesday, May 13, 2025, and the issue will conclude on Friday, May 16, 2025. The company intends to raise 29.75 crore from the offering and aims to be listed on the NSE Emerge platform.
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
"Millions Lost in the Shadows: Uncovering the Hidden Costs of Ineffective Procurement Strategies in the Pharmaceutical Industry As the pharmaceutical industry grapples with rising costs and shrinking profit margins, a stealthy culprit is quietly draining resources: procurement mistakes. A new report reveals that inadequate procurement practices are costing pharma businesses millions, threatening the very foundation of their operations.
88
88
Signup to get articles personalized to your interests!
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
"Millions Lost in the Shadows: Uncovering the Hidden Costs of Ineffective Procurement Strategies in the Pharmaceutical Industry As the pharmaceutical industry grapples with rising costs and shrinking profit margins, a stealthy culprit is quietly draining resources: procurement mistakes. A new report reveals that inadequate procurement practices are costing pharma businesses millions, threatening the very foundation of their operations.
Lupin announced that it has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Raltegravir Tablets USP, 600 mg. Raltegravir Tablets are bioequivalent to Isentress HD Tablets, 600 mg of Merck Sharp & Dohme. Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity.
A gene editing drug custom-made for a critically ill baby showed that, for some ultra-rare diseases, it’s possible to design and test a new CRISPR medicine in just a few months.
Newron Pharmaceuticals has announced the approval for its ENIGMA-TRS phase 3 development programme evaluating evenamide as an add-on therapy to current antipsychotics in patients with treatment-resistant schizophrenia (TRS). This is a significant milestone Newrons endeavour to rollout the therapy as a conventional treatment for these patients. The ENIGMA-TRS phase 3 development programme consists of two […] The post Newrons programme for treatment-resistant schizophrenia therapy approved a
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
For a recent therapy session, Andria Donaghy’s insurance plan paid her psychiatric nurse practitioner only $11 on a $125 service. “To even put that on paper is insulting,” she said. “These people give their lives [to help others] and that’s what you pay them?
Ever tried shouting in a crowded stadium? Thats what it feels like launching a branded healthcare campaign today. With every pharma brand, health system, and startup clamoring for attention, crafting a successful healthcare marketing strategy has never been more challengingor more necessary. In 2025, reaching healthcare professionals (HCPs), patients, and caregivers requires more than budget and brand equity.
ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including neurology, immunology and cancer.
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
A global survey by Johnson & Johnson MedTech has revealed that a majority of Europeans are willing to share their health data in exchange for more personalised care signalling growing public trust in the role of technology in healthcare. Conducted between August and September 2024, the survey gathered responses from both the general public […] The post Majority of Europeans trust technology to improve healthcare, Johnson & Johnson survey finds appeared first on Pharmafile.
As a primary care physician serving Medicaid patients, I recently witnessed a preventable hospitalization that perfectly illustrates America’s health care dysfunction. My homebound patient with heart failure needed a routine lab test to adjust their medication. While commercially insured patients can access electronic lab orders, my patient’s Medicaid plan contracted exclusively with a laboratory requiring physical forms by mail.
The Federation of Asian Biotech Associations (FABA), Indian Immunologicals (IIL), and Agri Biotech Foundation (ABF) jointly inaugurated a finishing school programme at the Agri Biotech Foundation campus, Rajendra Nagar, Hyderabad. This programme gap between academic learning and industry readiness in biotechnology, The programme, which will run until June 4, 2025, provides intensive, hands-on training in wet lab facilities, offering real-world experience in microbiology, molecular biology, and c
A qualitative study aimed to strengthen systematic repurposing efforts within rare disease nonprofit organizations, while also providing a framework for data-driven drug repurposing.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical acute pain. Viatris now plans to file for approval this year.
The now 13-year-long legal saga over who invented CRISPR took yet another unexpected turn on Monday, in a ruling that could not only change U.S. ownership of patent rights to the groundbreaking gene-editing technology but more broadly redefine how the law determines when an invention has been made. The U.S. Court of Appeals for the Federal Circuit sided with the University of California and the University of Vienna in their bid to revive a fight over foundational CRISPR-Cas9 patents that t
In a world of podcasts , reels, and AI-written content, its fair to ask: are white papers still pulling their weight in pharma marketing? For teams navigating omnichannel campaigns, strict MLR approvals, and buyer fatigue, the answer isn’t just “yes”it’s if done right, they work better than ever. Once the domain of technical audiences and B2B legacy brands, white papers have evolved.
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
India may today account for less than 23 per cent of the pharma CDMO market today but has the potential to grow from $3.5 billion to $25 billion. Dr Abdelaziz Toumi, CEO, Lupin Manufacturing Solutions (LMS), explains to Viveka Roychowdhury how LMS is aligning long-term strategies, repositioning key assets, lining up investments in new modalities and leveraging Indias API ecosystem to capitalise on this opportunity.
Shares of the biotech fell around 15% on news the FDA is not only taking longer to review the drug, but will assemble an outside group of advisers to evaluate it as well.
WASHINGTON — In hours of combative congressional hearings Wednesday, health secretary Robert F. Kennedy Jr. swung between defending sweeping changes at his agency and backtracking on aspects of a reorganization he nevertheless said would be “painful.” He repeatedly cast doubts on reports about negative impacts of the changes, often calling them a “canard.
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
STEERLife, the life sciences division of STEER World, is advancing the development and manufacturing of potent and complex drug products. At the core of this advancement is STEERLife’s solvent-free melt fusion technology, a continuous processing system that eliminates the need for harmful organic solvents. Designed to handle high-potency and hard-to-develop molecules, this platform significantly enhances formulation efficiency, safety, and scalability.
The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and operational investments in U.S. drug manufacturing.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
358 
Let's personalize your content